NAD(P)H quinone oxidoreductase protects TAp63γ from proteasomal degradation and regulates TAp63γ-dependent growth arrest

PLoS ONE

Volumn 5, Issue 6, 2010, Pages

  Rokah, Oshrat Hershkovitz ^a   Shpilberg, Ofer ^a,b   Granot, Galit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ISOPROTEIN; PROTEASOME; PROTEIN P21; PROTEIN P63; PROTEIN TAP63GAMMA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL STRESS; CONTROLLED STUDY; DOWN REGULATION; ENZYME INACTIVATION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PROTEIN DEGRADATION; PROTEIN POLYMORPHISM; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; UPREGULATION; WILD TYPE;

BASE SEQUENCE; CELL DIVISION; CELL LINE; DNA PRIMERS; GENE SILENCING; HUMANS; HYDROLYSIS; IMMUNOPRECIPITATION; NAD(P)H DEHYDROGENASE (QUINONE); PROTEASOME ENDOPEPTIDASE COMPLEX; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 77955321215     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011401     Document Type: Article

References (41)

1. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, et al. (1998) p63, a p53 homolog at 3q27-29., encodes multiple products with transactivating, deathinducing, and dominant-negative activities. Mol Cell 2: 305-316.
2. Osada M, Park HL, Nagakawa Y, Yamashita K, Fomenkov A, et al. (2005) Differential recognition of response elements determines target gene specificity for p53 and p63. Mol Cell Biol 25: 6077-6089.
3. Osada M, Ohba M, Kawahara C, Ishioka C, Kanamaru R, et al. (1998) Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat Med 4: 839-843.
4. Zeng SX, Dai MS, Keller DM, Lu H (2002) SSRP1 functions as a co-activator of the transcriptional activator p63. EMBO J 21: 5487-5497.
5. Kaelin WG, Jr. (1999) The p53 gene family. Oncogene 18: 7701-7705.
6. Urist MJ, Di Como CJ, Lu ML, Charytonowicz E, Verbel D, et al. (2002) Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol 161: 1199-1206.
7. Koga F, Kawakami S, Fujii Y, Saito K, Ohtsuka Y, et al. (2003) Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin Cancer Res 9: 5501-5507.
8. Moll UM, Slade N (2004) p63 and p73: Roles in development and tumor formation. Mol Cancer Res 2: 371-386.
9. Pietsch EC, Sykes SM, McMahon SB, Murphy ME (2008) The p53 family and programmed cell death. Oncogene 27: 6507-6521.
10. Massion PP, Taflan PM, Jamshedur Rahman SM, Yildiz P, Shyr Y, et al. (2003) Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res 63: 7113-7121.
11. Park BJ, Lee SJ, Kim JI, Lee SJ, Lee CH, et al. (2000) Frequent alteration of p63 expression in human primary bladder carcinomas. Cancer Res 60: 3370-3374.
12. Marchini S, Marabese M, Marrazzo E, Mariani P, Cattaneo D, et al. (2008) DeltaNp63 expression is associated with poor survival in ovarian cancer. Ann Oncol 19: 501-507.
13. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, et al. (1999) p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398: 708-713.
14. Brooks CL, Gu W (2006) p53 ubiquitination: Mdm2 and beyond. Mol Cell 21: 307-315.
15. Papoutsaki M, Moretti F, Lanza M, Marinari B, Sartorelli V, et al. (2005) A p38-dependent pathway regulates DeltaNp63 DNA binding to p53-dependent promoters in UV-induced apoptosis of keratinocytes. Oncogene 24: 6970-6975.
16. Rossi M, Aqeilan RI, Neale M, Candi E, Salomoni P, et al. (2006) The E3 ubiquitin ligase Itch controls the protein stability of p63. Proc Natl Acad Sci USA 103: 12753-12758.
17. Bergamaschi D, Samuels Y, Jin B, Duraisingham S, Crook T, et al. (2004) ASPP1 and ASPP2: common activators of p53 family members. Mol Cell Biol 24: 1341-1350.
18. Bernassola F, Oberst A, Melino G, Pandolfi PP (2005) The promyelocytic leukaemia protein tumour suppressor functions as a transcriptional regulator of p63. Oncogene 24: 6982-6986.
19. Koutsodontis G, Vasilaki E, Chou WC, Papakosta P, Kardassis D (2005) Physical and functional interactions between members of the tumour suppressor p53 and the Sp families of transcription factors: importance for the regulation of genes involved in cell-cycle arrest and apoptosis. Biochem J 389: 443-455.
20. MacPartlin M, Zeng S, Lee H, Stauffer D, Jin Y, et al. (2005) p300 regulates p63 transcriptional activity. J Biol Chem 280: 30604-306010.
21. Fagerholm R, Hofstetter B, Tommiska J, Aaltonen K, Vrtel R, et al. (2008) NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 40: 844-853.
22. Sanyal S, Ryk C, De Verdier PJ, Steineck G, Larsson P, et al. (2007) Polymorphisms in NQO1 and the clinical course of urinary bladder neoplasms. Scand J Urol Nephrol 41: 182-190.
23. Chao C, Zhang ZF, Berthiller J, Boffetta P, Hashibe M (2006) NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15: 979-987.
24. Asher G, Bercovich Z, Tsvetkov P, Shaul Y, Kahana C (2005) 20S proteasomal degradation of ornithine decarboxylase is regulated by NQO1. Mol Cell 17: 645-655.
25. Garate M, Wong RP, Campos EI, Wang Y, Li G (2008) NAD(P)H quinone oxidoreductase 1 inhibits the proteasomal degradation of the tumour suppressor p33(ING1b). EMBO Rep 9: 576-581.
26. Asher G, Lotem J, Cohen B, Sachs L, Shaul Y (2001) Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proc Natl Acad Sci USA 98: 1188-1193.
27. Asher G, Lotem J, Kama R, Sachs L, Shaul Y (2002) NQO1 stabilizes p53 through a distinct pathway. Proc Natl Acad Sci USA 9: 3099-3104.
28. Asher G, Lotem J, Sachs L, Kahana C, Shaul Y (2002) Mdm-2 and ubiquitinindependent p53 proteasomal degradation regulated by NQO1. Proc Natl Acad Sci USA 99: 13125-13130.
29. Asher G, Tsvetkov P, Kahana C, Shaul Y (2005) A mechanism of ubiquitinindependent proteasomal degradation of the tumor suppressors p53 and p73. Genes Dev 19: 316-321.
30. Vindelov LL, Christensen IJ, Nissen NI (1983) A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3: 323-327.
31. Siegel D, Anwar A, Winski SL, Kepa JK, Zolman KL, et al. (2001) Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1. Mol Pharmacol 59: 263-268.
32. Traver RD, Siegel D, Beall HD, Phillips RM, Gibson NW, et al. (1997) Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DTdiaphorase). Br J Cancer 75: 69-75.
33. Cross JV, Deak JC, Rich EA, Qian Y, Lewis M, et al. (1999) Quinone reductase inhibitors block SAPK/JNK and NFkappaB pathways and potentiate apoptosis. J Biol Chem 274: 31150-31154.
34. Reigan P, Colucci MA, Siegel D, Chilloux A, Moody CJ, et al. (2007) Development of indolequinone mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1): NQO1 inhibition and growth inhibitory activity in human pancreatic MIA PaCa-2 cancer cells. Biochemistry 46: 5941-5950.
35. Petitjean A, Ruptier C, Tribollet V, Hautefeuille A, Chardon F, et al. (2008) Properties of the six isoforms of p63: p53-like regulation in response to genotoxic stress and cross talk with DeltaNp73. Carcinogenesis 29: 273-281.
36. Katoh I, Aisaki KI, Kurata SI, Ikawa S, Ikawa Y (2000) p51A (TAp63gamma), a p53 homolog, accumulates in response to DNA damage for cell regulation. Oncogene 19: 3126-3130.
37. Okada Y, Osada M, Kurata S, Sato S, Aisaki K, et al. (2002) p53 gene family p51(p63)-encoded, secondary transactivator p51B (TAp63alpha) occurs without forming an immunoprecipitable complex with MDM2, but responds to genotoxic stress by accumulation. Exp Cell Res 276: 194-200.
38. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, et al. (2004) Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119: 861-872.
39. Gressner O, Schilling T, Lorenz K, Schulze Schleithoff E, Koch A, et al. (2005) TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J 24: 2458-2471.
40. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, et al. (2002) p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416: 560-564.
41. Crook T, Nicholls JM, Brooks L, O'Nions J, Allday MJ (2000) High-level expression of deltaN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)? Oncogene 19: 3439-3444.